Physicians' Academy for Cardiovascular Education

Improving quality of life in patients with HCM

10' education - Oct. 5, 2023 - Carolyn Ho, MD - Boston, MA, USA

Video navigation menu

  • HCM pathophysiology 00:23
  • Traditional therapies for HCM 01:35
  • Cardiac myosin inhibitors 03:07
  • Clinical trials with cardiac myosin inhibitors 04:26
  • Where do myosin inhibitors currently fit into practice? 09:29

What was observed in the REDWOOD-HCM Cohort 4 trial in patients with symptomatic non-obstructive HCM? Treatment with the myosin inhibitor aficamten ...

  • A. led to improvements in NYHA functional classes, and these effects regressed after a 2-week wash-out period.
  • B. worsened NYHA functional classes.
  • C. improved the KCCQ-CSS score by 9.1 points.
  • D. provided adequate clinical improvements for patients to defer invasive SRT.
Show the correct answer


Show transcript

Educational information

This lecture by Carolyn Ho, MD was part of the EBAC-accredited symposium "Seeing the forest through the trees - Diagnosing and treating hypertrophic cardiomyopathy" held at the ESC Congress 2023, Amsterdam, The Netherlands.


Carolyn Ho is Associate Professor of Medicine at Harvard Medical School and Medical Director of the Cardiovascular Genetics Center at Brigham and Women’s Hospital in Boston, MA, USA.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Cytokinetics.

Find here the slides of the presentation Watch the other videos of this series

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: